|
1
|
André T, Tougeron D, Piessen G, de la
Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio
T, Desrame J, et al: Neoadjuvant nivolumab plus ipilimumab and
adjuvant nivolumab in localized deficient mismatch
repair/microsatellite instability-high gastric or esophagogastric
junction adenocarcinoma: The GERCOR NEONIPIGA phase II study. J
Clin Oncol. 41:255–265. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Castro G Jr, Kudaba I, Wu YL, Lopes G,
Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B,
Laktionov KK, et al: Five-year outcomes with pembrolizumab versus
chemotherapy as first-line therapy in patients with non-small-cell
lung cancer and programmed death ligand-1 tumor proportion score
≥1% in the KEYNOTE-042 study. J Clin Oncol. 41:1986–1991. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park JW, Chang HJ, Yeo HY, Han N, Kim BC,
Kong SY, Kim J and Oh JH: The relationships between systemic
cytokine profiles and inflammatory markers in colorectal cancer and
the prognostic significance of these parameters. Br J Cancer.
123:610–618. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sullivan RJ and Weber JS: Immune-related
toxicities of checkpoint inhibitors: Mechanisms and mitigation
strategies. Nat Rev Drug Discov. 21:495–508. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US Food
and Drug Administration (FDA) approvals of immune checkpoint
inhibitors. J Immunother Cancer. 7:2782019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wan L, Wang Z, Xue J, Yang H and Zhu Y:
Tumor mutation burden predicts response and survival to immune
checkpoint inhibitors: A meta-analysis. Transl Cancer Res.
9:5437–5449. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valero C, Lee M, Hoen D, Wang J, Nadeem Z,
Patel N, Postow MA, Shoushtari AN, Plitas G, Balachandran VP, et
al: The association between tumor mutational burden and prognosis
is dependent on treatment context. Nat Genet. 53:11–15. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang CL, Gao MQ, Jiang XC, Pan X, Zhang
XY, Li Y, Shen Q, Chen Y and Pang B: Research progress and value of
albumin-related inflammatory markers in the prognosis of non-small
cell lung cancer: A review of clinical evidence. Ann Med.
55:1294–1307. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tada H, Kawabata-Iwakawa R, Takahashi H
and Chikamatsu K: Novel index based on inflammatory markers
correlates with treatment efficacy of nivolumab for
recurrent/metastatic head and neck cancer. Oncology. Nov
20–2024.(Epub ahead of print). View Article : Google Scholar
|
|
10
|
Shayimu P, Awula M, Wang CY, Jiapaer R,
Pan YP, Wu ZM, Chen Y and Zhao ZL: Serum nutritional predictive
biomarkers and risk assessment for anastomotic leakage after
laparoscopic surgery in rectal cancer patients. World J
Gastrointest Surg. 16:3142–3154. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cederholm T, Bosaeus I, Barazzoni R, Bauer
J, Van Gossum A, Klek S, Muscaritoli M, Nyulasi I, Ockenga J,
Schneider SM, et al: Diagnostic criteria for malnutrition-an ESPEN
consensus statement. Clin Nutr. 34:335–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Li Z, Huang Z, Yu X, Zheng L and
Xu J: C-reactive protein is an indicator of the immunosuppressive
microenvironment fostered by myeloid cells in hepatocellular
carcinoma. Front Oncol. 11:7748232021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Z, Sun Y, Wang J, Shen X, Chen L and
Zhuang Z: Prognostic and predictive value of serum C-reactive
protein levels in patients with metastatic or locally recurrent
gastric cancer. Int J Biol Markers. 31:e294–r299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nießen A, Schimmack S, Sandini M, Fliegner
D, Hinz U, Lewosinska M, Hackert T, Büchler MW and Strobel O:
C-reactive protein independently predicts survival in pancreatic
neuroendocrine neoplasms. Sci Rep. 11:237682021. View Article : Google Scholar
|
|
16
|
Zhang Y, Lu L, He Z, Xu Z, Xiang Z, Nie
RC, Lin W, Chen W, Zhou J, Yin Y, et al: C-reactive protein levels
predict responses to PD-1 inhibitors in hepatocellular carcinoma
patients. Front Immunol. 13:8081012022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Demir O, Demirag G and Aslan G:
Prospective evaluation of hematological parameters in preoperative
renal cell cancer patients. BMC Urol. 22:2012022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steinhagen F, Schmidt SV, Schewe JC,
Peukert K, Klinman DM and Bode C: Immunotherapy in sepsis-brake or
accelerate? Pharmacol Ther. 208:1074762020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Comparison of an inflammation-based
prognostic score (GPS) with performance status (ECOG) in patients
receiving platinum-based chemotherapy for inoperable non-small-cell
lung cancer. Br J Cancer. 90:1704–1706. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McMillan DC, Crozier JE, Canna K, Angerson
WJ and McArdle CS: Evaluation of an inflammation-based prognostic
score (GPS) in patients undergoing resection for colon and rectal
cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watt DG, Roxburgh CS, White M, Chan JZ,
Horgan PG and McMillan DC: A survey of attitudes towards the
clinical application of systemic inflammation based prognostic
scores in cancer. Mediators Inflamm. 2015:8420702015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dolan RD, McSorley ST, Park JH, Watt DG,
Roxburgh CS, Horgan PG and McMillan DC: The prognostic value of
systemic inflammation in patients undergoing surgery for colon
cancer: Comparison of composite ratios and cumulative scores. Br J
Cancer. 119:40–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tanaka T, Yoshida T, Masuda K, Takeyasu Y,
Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N
and Ohe Y: Prognostic role of modified Glasgow prognostic score in
elderly non-small cell lung cancer patients treated with anti-PD-1
antibodies. Respir Investig. 61:74–81. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kawakami H, Sunakawa Y, Inoue E, Matoba R,
Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, et
al: Soluble programmed cell death ligand 1 predicts prognosis for
gastric cancer patients treated with nivolumab: Blood-based
biomarker analysis for the DELIVER trial. Eur J Cancer. 184:10–20.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. Syst Rev. 10:892021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Chen S, Chen H and Li W: A
comprehensive analysis of Glasgow prognostic score (GPS)/the
modified Glasgow prognostic score (mGPS) on immune checkpoint
inhibitor efficacy among patients with advanced cancer. Cancer Med.
12:38–48. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wells GA, Shea BJ, O'Connell D, Peterson
J, Welch V, Losos M and Tugwell P: The Newcastle Ottawa scale (NOS)
for assessing the quality of non-randomised studies in
meta-analyses. World J Cardiovasc Dis. May 28–2021.(Epub ahead of
print).
|
|
28
|
Sakai D, Omori T, Fumita S, Fujita J,
Kawabata R, Matsuyama J, Yasui H, Hirao M, Kawase T, Kishi K, et
al: Real-world effectiveness of third- or later-line treatment in
Japanese patients with HER2-positive, unresectable, recurrent or
metastatic gastric cancer: A retrospective observational study. Int
J Clin Oncol. 27:1154–1163. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Z, Zhang D, Zeng H, Fu Y, Hu Z, Pan
Y, Chen J, Wang J, Zhang Y, Zhou Z, et al: Inflammation-based
scores predict responses to PD-1 inhibitor treatment in
intrahepatic cholangiocarcinoma. J Inflamm Res. 15:5721–5731. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kurosaki T, Kawakami H, Mitani S, Kawabata
R, Takahama T, Nonagase Y, Fumita S, Ozaki T, Chiba Y, Tamura T and
Nakagawa K: Glasgow prognostic score (GPS) and tumor response as
biomarkers of nivolumab monotherapy in third-or later-line setting
for advanced gastric cancer. In Vivo. 34:1921–1929. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang HS, Shin AY, Yeo CD, Kim SK, Park CK,
Kim JS, Kim SJ, Lee SH and Kim JW: Significance of Glasgow
prognostic scores in NSCLC patients treated with immunotherapy
after platinum-based cytotoxic chemotherapy. In Vivo. 35:3423–3430.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Minichsdorfer C, Gleiss A, Aretin MB,
Schmidinger M and Fuereder T: Serum parameters as prognostic
biomarkers in a real world cancer patient population treated with
anti PD-1/PD-L1 therapy. Ann Med. 54:1339–1349. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Namikawa T, Yokota K, Tanioka N, Fukudome
I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M
and Hanazaki K: Systemic inflammatory response and nutritional
biomarkers as predictors of nivolumab efficacy for gastric cancer.
Surg Today. 50:1486–1495. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kasajima M, Igawa S, Manaka H, Yamada K,
Akazawa Y, Manabe H, Yagami Y, Yamamoto H, Ito H, Kaizuka N, et al:
The Glasgow prognostic score predicts outcomes of pembrolizumab or
atezolizumab monotherapy in patients with pretreated non-small cell
lung cancer. Oncology. 101:69–76. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim JH, Ahn B, Hong SM, Jung HY, Kim DH,
Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, et al: Real-world efficacy
data and predictive clinical parameters for treatment outcomes in
advanced esophageal squamous cell carcinoma treated with immune
checkpoint inhibitors. Cancer Res Treat. 54:505–516. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tokuyama N, Takegawa N, Nishikawa M, Sakai
A, Mimura T, Kushida S, Tsumura H, Yamamoto Y, Miki I and Tsuda M:
Pretreatment Glasgow prognostic score as a predictor of outcomes in
nivolumab-treated patients with advanced gastric cancer. PLoS One.
16:e02476452021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujiwara R, Takemura K, Fujiwara M, Yuasa
T, Yasuoka S, Komai Y, Numao N, Yamamoto S and Yonese J: Modified
Glasgow prognostic score as a predictor of prognosis in metastatic
renal cell carcinoma treated with nivolumab. Clin Genitourin
Cancer. 19:e78–e83. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matsuki T, Okamoto I, Fushimi C, Sawabe M,
Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, et al:
Hematological predictive markers for recurrent or metastatic
squamous cell carcinomas of the head and neck treated with
nivolumab: A multicenter study of 88 patients. Cancer Med.
9:5015–5024. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brown JT, Liu Y, Martini DJ, Shabto JM,
Russler G, Caulfield S, Yantorni LB, Joshi SS, Kissick H, Ogan K,
et al: Baseline modified Glasgow prognostic score (mGPS) in
patients with metastatic renal cell carcinoma (mRCC) treated with
immune checkpoint inhibitors (ICI). J Clin Oncol. 39 (Suppl
15):e165462021. View Article : Google Scholar
|
|
40
|
Brown JT, Liu Y, Shabto JM, Martini D,
Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni L,
Joshi SS, et al: Modified Glasgow prognostic score associated with
survival in metastatic renal cell carcinoma treated with immune
checkpoint inhibitors. J Immunother Cancer. 9:e0028512021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Freitas C, Jacob M, Tavares N,
Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V,
Fernandes G, Magalhães A, et al: Modified Glasgow prognostic score
predicts survival among advanced non-small cell lung carcinoma
patients treated with anti-PD1 agents. Anticancer Drugs.
32:567–574. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Diker O and Olgun P: Association of the
immune-inflammation-nutritional parameters with immune checkpoint
inhibitor outcomes in patients with advanced non-small cell lung
cancer. J Oncol Sci. 8:43–53. 2022. View Article : Google Scholar
|
|
43
|
Pflug N, Vitus M, Knuever J, Hamacher S,
Mauch C, Schlaak M and Theurich S: Treatment-specific evaluation of
the modified Glasgow-prognostic-score in patients with advanced
cutaneous melanoma. J Eur Acad Dermatol Venereol. 35:e879–e883.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ogura Y, Kataoka N, Kunimatsu Y, Tachibana
Y, Sugimoto T, Tani N, Sato I, Hirose K, Kato D and Takeda T:
Predictors of survival among Japanese patients receiving first-line
chemoimmunotherapy for advanced non-small cell lung cancer. Thorac
Cancer. 12:97–105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Niwa K, Kawakita D, Nagao T, Takahashi H,
Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, et
al: Multicentre, retrospective study of the efficacy and safety of
nivolumab for recurrent and metastatic salivary gland carcinoma.
Sci Rep. 10:169882020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
McMillan DC: The systemic
inflammation-based Glasgow prognostic score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Luo B, Zhang Y, Zhu X, Ji T, Wu K, Sun D,
Lu Y and Shi L: Prognostic impact of the high-sensitivity modified
glasgow prognostic score on patients undergoing radical surgery for
hepatocellular carcinoma: Authorship. Langenbecks Arch Surg.
409:2232024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yamanouchi K, Murakami S, Sato A, Ogawa S,
Shinagawa H and Kamohara Y: Integrated evaluation of inflammatory,
nutritional, and sarcopenia markers to predict survival in
metastatic breast cancer patients. In Vivo. 37:811–817. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kinoshita A, Onoda H, Imai N, Iwaku A,
Oishi M, Fushiya N, Koike K, Nishino H and Tajiri H: Comparison of
the prognostic value of inflammation-based prognostic scores in
patients with hepatocellular carcinoma. Br J Cancer. 107:988–993.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Ohtaki M, Ohtani K, Shiragami M, Fujimura Y, Hayashi M, Shinozaki N
and Minami H: Inflammation-based prognostic markers in patients
with advanced or recurrent gastric cancer treated with nivolumab:
Tokushukai REAl-world data project 02 (TREAD 02). Mol Clin Oncol.
21:902024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lorton CM, Higgins L, O'Donoghue N,
Donohoe C, O'Connell J, Mockler D, Reynolds JV, Walsh D and Lysaght
J: C-reactive protein and C-reactive protein-based scores to
predict survival in esophageal and junctional adenocarcinoma:
Systematic review and meta-analysis. Ann Surg Oncol. 29:1853–1865.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Potempa LA, Rajab IM, Olson ME and Hart
PC: C-reactive protein and cancer: Interpreting the differential
bioactivities of its pentameric and monomeric, modified isoforms.
Front Immunol. 12:7441292021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sproston NR and Ashworth JJ: Role of
C-reactive protein at sites of inflammation and infection. Front
Immunol. 9:7542018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yoshida T, Ichikawa J, Giuroiu I, Laino
AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F and
Weber J: C reactive protein impairs adaptive immunity in immune
cells of patients with melanoma. J Immunother Cancer.
8:e0002342020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bilen MA, Martini DJ, Liu Y, Lewis C,
Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, et
al: The prognostic and predictive impact of inflammatory biomarkers
in patients who have advanced-stage cancer treated with
immunotherapy. Cancer. 125:127–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zheng X, Zhang L, Wu L, Zhao J, Sun J,
Fang Y, Zhou J, Chu Q, Shen Y, Yang Z, et al: Baseline C-reactive
protein predicts efficacy of the first-line immune checkpoint
inhibitors plus chemotherapy in advanced lung squamous cell
carcinoma: A retrospective, multicenter study. BMC Cancer.
23:12442023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang H, Yang R, Zhou K, Wang S, Cheng C,
Liu D and Li W: Association between pretreatment C-reactive protein
level and survival in non-small cell lung cancer patients treated
with immune checkpoint inhibitors: A meta-analysis. Int
Immunopharmacol. 124:1109372023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kijima T, Yamamoto H, Saito K, Kusuhara S,
Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Sakai Y, Matsubara N,
et al: Early C-reactive protein kinetics predict survival of
patients with advanced urothelial cancer treated with
pembrolizumab. Cancer Immunol Immunother. 70:657–665. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Keller U: Nutritional laboratory markers
in malnutrition. J Clin Med. 8:7752019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yoo SK, Chowell D, Valero C, Morris LGT
and Chan TA: Pre-treatment serum albumin and mutational burden as
biomarkers of response to immune checkpoint blockade. NPJ Precis
Oncol. 6:232022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guo Y, Wei L, Patel SH, Lopez G, Grogan M,
Li M, Haddad T, Johns A, Ganesan LP, Yang Y, et al: Serum albumin:
Early prognostic marker of benefit for immune checkpoint inhibitor
monotherapy but not chemoimmunotherapy. Clin Lung Cancer.
23:345–355. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Roxburgh CS and McMillan DC: Role of
systemic inflammatory response in predicting survival in patients
with primary operable cancer. Future Oncol. 6:149–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Argilés JM, Busquets S, Stemmler B and
López-Soriano FJ: Cancer cachexia: Understanding the molecular
basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Soeters PB, Wolfe RR and Shenkin A:
Hypoalbuminemia: Pathogenesis and clinical significance. JPEN J
Parenter Enteral Nutr. 43:181–193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kose E, Wakabayashi H and Yasuno N:
Polypharmacy and malnutrition management of elderly perioperative
patients with cancer: A systematic review. Nutrients. 13:19612021.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Daniele A, Divella R, Abbate I,
Casamassima A, Garrisi VM, Savino E, Casamassima P, Ruggieri E and
DE Luca R: Assessment of nutritional and inflammatory status to
determine the prevalence of malnutrition in patients undergoing
surgery for colorectal carcinoma. Anticancer Res. 37:1281–1287.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Unal D, Eroglu C, Ozsoy SD, Besirli A,
Orhan O and Kaplan B: Effect on long-term survival of psychiatric
disorder, inflammation, malnutrition, and radiotherapy-related
toxicity in patients with locally advanced head and neck cancer. J
BUON. 886–893. 2015.PubMed/NCBI
|
